Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis

Página do item simplificado
dc.citation.issue4
dc.citation.volume83
dc.contributor.authorHermann, Juliana Sato [UNIFESP]
dc.contributor.authorWeckx, Lily Yin [UNIFESP]
dc.contributor.authorNurmberger, Jussimara Monteiro
dc.contributor.authorSantos Junior, Gildo Francisco dos
dc.contributor.authorPignatari, Antonio Carlos Campos [UNIFESP]
dc.contributor.authorPignatari, Shirley Shizue Nagata [UNIFESP]
dc.coverageClare
dc.date.accessioned2020-07-22T13:23:19Z
dc.date.available2020-07-22T13:23:19Z
dc.date.issued2016
dc.description.abstractObjective: To evaluate whether the quadrivalent human papillomavirus (HPV) (types 6, 11, 16, and 18) vaccine influences the clinical course of juvenile-onset recurrent respiratory papillomatosis (RRP) when administered to a group of patients with this condition. Methods: Uncontrolled intervention study of patients with juvenile-onset RRP examined at the Pediatric Otorhinolaryngology Clinic, Federal University of Sao Paulo, where nine patients between the ages of nine and 17 received three doses of the prophylactic quadrivalent HPV vaccine (Gardasil) and were followed for one year. Disease staging, intervals between relapses, intervals between surgeries, and the number of surgeries during the year prior to vaccination and during the first year after vaccination were compared. Results: Eight patients were infected with HPV-6 and one with HPV-11. There were no statistically significant differences in the clinical scores (p = 0.083), anatomical scores (p = 0.257), intervals between relapses (p = 0.062), intervals between surgeries (p = 0.357), or the numbers of surgeries (p = 0.180) when the years before and after vaccination were compared. All patients had relapses following vaccination. Conclusion: Patients with juvenile-onset RRP experienced a similar clinical course in the year after versus the year before vaccination with Gardasil. (C) 2016 Elsevier Ireland Ltd. All rights reserved.en
dc.description.affiliationUniv Fed Sao Paulo, Discipline Pediat Otorhinolaryngol, Sao Paulo, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Dept Pediat, Sao Paulo, Brazil
dc.description.affiliationRes Incent Fund Assoc, Sao Paulo, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Discipline Infect Dis, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Discipline Pediat Otorhinolaryngol, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Pediat, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Discipline Infect Dis, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent94-98
dc.identifierhttp://dx.doi.org/10.1016/j.ijporl.2016.01.032
dc.identifier.citationInternational Journal Of Pediatric Otorhinolaryngology. Clare, v. 83, n. 4, p. 94-98, 2016.
dc.identifier.doi10.1016/j.ijporl.2016.01.032
dc.identifier.issn0165-5876
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/56169
dc.identifier.wosWOS:000372941700020
dc.language.isoeng
dc.publisherElsevier Ireland Ltd
dc.relation.ispartofInternational Journal Of Pediatric Otorhinolaryngology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectPapillomaen
dc.subjectPapillomavirus vaccinesen
dc.subjectPapillomavirus infectionsen
dc.subjectChilden
dc.subjectTreatment outcomeen
dc.titleEffectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosisen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos